Assessment of the Tolerability and Safety in Humans of a New Adjuvanted Anti-allergic Therapeutic Vaccine

Rationale Novel therapeutic vaccines for allergic asthma, based on House Dust Mite allergens, effective with fewer administration would be a very advantageous alternative over conventional allergy vaccines and would allow a greater extension of the immunotherapy approach, reducing the consumption of...

Full description

Saved in:
Bibliographic Details
Published in:Journal of allergy and clinical immunology 2018-02, Vol.141 (2), p.AB172-AB172
Main Authors: Reyes Zamora, Mary C., Castro Almarales, Raul L., Mateo Morejon, Maytee, Ramirez González, Wendy, Torralba Averoff, Damaris, Ronquillo Diaz, Mercedes, González Paredes, Alina C., Tamayo Gutierrez, Maria A., Castelló, Mirta Álvarez, Rodriguez Canosa, Jose S., Perez, Oliver, Rosado, Alexis Labrada
Format: Article
Language:English
Subjects:
Allergies
Neisseria meningitidis
Vaccines
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Rationale Novel therapeutic vaccines for allergic asthma, based on House Dust Mite allergens, effective with fewer administration would be a very advantageous alternative over conventional allergy vaccines and would allow a greater extension of the immunotherapy approach, reducing the consumption of symptomatic medications. In Cuba and other Caribbean countries the species Dermatophagoides siboney is very relevant as a cause of respiratory allergy.The objective of this research was to perform the first evaluation in humans of the tolerability and safety of a D. siboney allergen vaccine, adjuvanted with Neisseria meningitidis B proteoliposome (PROLINEM-DS).
ISSN:0091-6749
1097-6825
DOI:10.1016/j.jaci.2017.12.548